Vector based shRNA clones

Supplier
GeneCopoeia
Product
shRNA clones
Links
GeneCopoeia GeneCopoeia information

Features

• All shRNA target sequences are selected through a proprietary algorithm. shRNAs of varying lengths (19 to 29 bases) were used for different genes to make shRNA expression constructs that have high knockdown efficiency with minimal off-target effect.



• shRNAs are cloned into lentiviral and other mammalian vectors with various promoters and reporter genes.



• Vector plasmid transfection and transduction virus infection efficiency are monitored by EGFP reporter protein.



• Stable cell line selection marker (puromycin) and EGFP in the vector backbones enable studies of the effect of long term expression suppression as well as that of transient suppression.



• Lentiviral vector systems allow efficient transduction of shRNAs into non-dividing and difficult to transfect target cell lines as well as conventional dividing cells.



• The expression cassettes of all shRNA clones are fully sequenced, which includes the promoter, sense and antisense target sequences, hairpin, termination and other linker sequences.

OmicsLink™ shRNA clone collections consist of multiple sets of expression vector based small hairpin RNAi (shRNA) clones against genome-wide target genes from human, mouse, and other species. Researchers can use these shRNA clones to study the loss-of-function of corresponding genes/proteins. We also offer multiple sets of full length human and mouse expression ready ORF cDNA clones that can be used for gain-of-function studies of corresponding target genes. These expression ready ORF clones are also available in special vectors and can be used for validation of shRNA clones.



Fig. 1. Lentiviral expression vector based shRNA clones with H1 or U6 promoter.
shRNA expression clones are available in both regular mammalian expression vector psi-H1™ and lentiviral expression systems (psiLv-H1™ andpsiLV-U6™), which enables both transient and stable gene silencing. Expression plasmid DNAs or viral particles containing shRNAs are introduced into target cells. A mammalian promoter (H1 or U6) is used to drive transcription of target sequences designed to form stems(19~29mers) and loops, which are then processed to generate siRNAs by the enzymes involved in RNAi machinery. Specific gene silencing is achieved as the result of cleavage and degradation of the mRNAs fortargeted genes by RISC-shRNA complexes (Fig. 2).



Fig. 2. The mechanism of shRNA vector mediated gene silencing.

The expression cassettes of all shRNA clones are fully sequenced, which includes the promoter, sense and antisense target sequences, hairpin, termination and other linker sequences. For human kinome shRNA clones in psi-sH1 vector, we provide 1 to 3 clones for each gene, all of which have been validated to have a KD effect of 70% of the original level using the surrogate colorimetric alkaline phosphatase assay. For lentiviral and mammalian vector based shRNAs, we provide 4 shRNA clone constructs for each gene. We guarantee that at least one of four shRNA constructs will have a KD effect of 70% on corresponding gene expression by 70% using at least one of the 4 aforementioned validation methods, provided that all verification experiments are conducted in strict adherence to the protocols and procedures provided by GeneCopoeia. After adequate trouble shooting procedure is complete and it is found that none of the four shRNA constructs can achieve guaranteed level of KD effect, we will supply a new set of 1 to 4 shRNA constructs free of charge.

• Single gene down-regulation. The knocking down (KD) effect of the shRNA clones for a single gene can be studied and compared with that of a scrambled nucleotide control clone.
• Pathway analysis. We have grouped genes into various signal transduction, metabolic, and disease pathways and associations, as well as gene families and groups. By arraying the shRNA clones of known pathway(s) in 96 or 384 well plates, the role for a group of genes can be studied in a pathway. Currently, we offer customers with a large collection of shRNA clones against the human kinome, which can be grouped according to the functionality of each kinase.
• Also available are expression ready ORF clones for the corresponding target genes in various vector types with different reporter tags or genes. These expression ready ORF clones together with the same ORF clones that contain silent mutations in shRNA target sequence regions can be used for shRNA validation studies and gene/protein functional rescue studies for genes/proteins targeted by corresponding shRNAs.
• Knockdown Measurement:

• q-RT-PCR. Targeting of the corresponding mRNA by a shRNA expressing cassette leads to cleavage and degradation of the mRNA and subsequent reduction of protein expression. q-RT-PCR is recommended as the first step in measuring KD effect. We offer validated q-RT-PCR primers for corresponding target genes (and any other published transcripts).
• Western blot analysis. Protein down-regulation is required in most cases for gene KD studies which can be assessed by Western Blot analysis. We offer more than 2,500 monoclonal and polyclonal antibodies against human proteins for use in Western Blot analysis.
• Functional assays. KD effect of shRNAs can be studied by end-point biological and biochemical assays such as cell proliferation, colony formation, cell cycle analysis, and migration, based on the potential role played by each gene/protein.
• Functional assays by a reporter gene/protein. Alternatively, when the endogenous transcript level of gene of interest is low and/or when q-RT-PCR and Western Blot analysis is not feasible or possible, KD effect can be measured by co-transduction of shRNA clone with an expression clone plasmid which is transcribed into a chimeric mRNA transcript consisting of a reporter gene and the target gene ORF. The reporter gene encodes a reporter protein enzyme that can be used in functional assays. The destruction of the target gene mRNA by targeting shRNA results in the degradation of the reporter gene and, therefore, translation reduction of reporter protein enzyme. The KD effect can be quantified by the reporter enzymatic assays. See figure 3 for an example of this validation method.

1. Identify the gene of interest:

Please gather as much as possible of the following information: Gene Description, species, Nucleotide Accession, Entrez Gene ID, Symbols/Aliases or Catalog/product ID. You can also submit a sequence so we can search by target gene sequences homology (BLAST)

Alternatively, you can use the search tool by GeneCoppoeia - Search shRNA target by GeneCopoeia - and order the product ID result.

2. Choose the vector(s) of interest:

Pick-up the shRNA expression system(s) you wish to use from the list (vectors details)

3. Fill out the order form:

and fill with requested information. Send it back to us by email or FAX. We will contact you shortly to confirm: sequences, vectors and controls